REGN241101P1010000
- 78.11
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,210, Maintains Outperform Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,080
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,260
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,175
Regeneron Pharma Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,250
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,080 to $1,242
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharma Is Maintained at Overweight by Barclays
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,050 to $1,242
Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1050
Regeneron Pharma Price Target Maintained With a $1260.00/Share by RBC Capital
Regeneron Pharmaceuticals Analyst Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $1,205 From $1,245
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,137
Regeneron Pharma Is Maintained at Buy by Truist Securities
Regeneron Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,235